Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Trial Profile

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Granulocyte macrophage colony stimulating factor
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PROSPECT
  • Sponsors Bavarian Nordic; BN ImmunoTherapeutics

Most Recent Events

  • 06 Apr 2022 This trial has been completed in Netherland (End Date: 02 Oct 2017), according to European Clinical Trials Database record.
  • 28 Feb 2019 Argentina,Austria, Brazil, Chile, Czech Republic,Lithuania, Mexico, Panama, Slovakia, Switzerland, were the planned locations as per European Clinical Trials Database record.
  • 28 Feb 2019 Results assessing median overall survival metastatic castration-resistant prostate cancer patients published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top